FDA Inspection
Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited – FDA Inspection, Sep 25, 2019
Record Details
This FDA Inspection record concerns Takeda Pharmaceutical Company Limited, with an inspection on September 25, 2019, issued by the Center for Biologics Evaluation and Research, covering biologics.
- People
- Allison A. Wellman (Issuing Officer)
- Burnell M. Henry (FDA Associated Person)
View Company Profile
ID · f815b5da-2d6a-4e03-8688-006a8fbebf36
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1103189
- FDA center
- Biologics
- Project area
- Blood and Blood Products
- Outcome
- Form 483 issued
FDA Citations
3- 21 CFR 640.81(c)Microbial contamination
- 21 CFR 807.22(a)Initial registration and listing
- 21 CFR 123.8(a)(3)(ii)Corrective action record review adequacy
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Takeda Pharmaceutical Company Limited
2| Date | Classification | Office | Project area |
|---|---|---|---|
| November 26, 2025 | Not classified | Chicago District Office | Blood and Blood Products |
| September 15, 2022 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
Other documents for Takeda Pharmaceutical Company Limited
- FDA Inspection 1293098 - 2025-11-26
- FDA Inspection 1179911 - 2022-09-15
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.